Gilead Sciences Inc
NASDAQ: GILD
$83.56
-$0.34 (-0.4%)
Real Time Data Delayed 15 Min.
GILD Articles
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Published:
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how they...
Published:
The run-up in equity prices related to the COVID-19 outbreak combined with the federal government's efforts to soften the financial damage due to the pandemic have driven equity prices sharply...
Published:
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Gilead has priced its COVID-19 drug candidate at $2,340 for a five-day treatment in the United States and some other developed countries. The company set the price for a single vial of remdesivir at...
Published:
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The new attitude among investors about sustainability and societal impact probably will dominate discussion and investment choices in the years to come. Here are five of RBC's top picks in the arena...
Published:
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Wednesday's top analyst upgrades and downgrades included Apache, Apple, CME, Devon Energy, Diamondback Energy, Gilead Sciences, Hexo, MarketAxess, Microchip Technology and Zoom Video Communications.
Published:
The May 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks was mixed.
Published:
In a world where investors are starving to find growth, many of the well established biotech leaders and many of the large pharmaceutical companies have been acquiring growth on top of their own...
Published:
Tuesday's top analyst upgrades and downgrades included Chembio Diagnostics, Cognex, Cree, Deere, Gilead Sciences, Halliburton, iRobot, Lam Research, Nvidia, Regeneron Pharmaceuticals, Sorrento...
Published:
Last Updated: